FDA Approves New Treatment for Rare Form of Thyroid Cancer
The U.S. Food and Drug Administration (FDA) today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.
